Jasper Therapeutics Announces Briquilimab Development Program in Asthma

May 13, 2024

https://www.globenewswire.com/news-release/2024/05/13/2880412/0/en/Jasper-Therapeutics-Announces-Briquilimab-Development-Program-in-Asthma.html

REDWOOD CITY, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced the expansion of its mast cell development portfolio with a Phase 1b/2a study evaluating briquilimab in asthma patients that is expected to begin enrolling in the fourth quarter of 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.